Everest Medicines Expands Strategic Investment in I-MAB to Approach the International Price of Its Proprietary Next-Expertise Cancer Immunotherapies

HONG KONG, Aug 2, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) at the new time launched a strategic fairness funding in I-Mab (NASDAQ: IMAB), below which Everest will invest US$30.9 million (the same to approximately HK$242.6 million) in cash. Upon completion of the subscription and inclusive of shares already held, Everest will possess approximately 16.1% of I-Mab’s total eminent shares.

Beneath the phrases of the agreement of this offering, Everest will subscribe for 15,846,154 newly issued American depositary shares (ADSs) of I-Mab at a label of US$1.95 per ADS, for a total consideration of US$30.9 million. Upon completion, Everest will defend a total of 15,846,154 ADSs and 6,078,571 frequent shares, representing approximately 16.1% of I-Mab’s total issued share capital, inclusive of 6,078,571 frequent shares it already owns. To boot to to Everest, several main world institutional merchants are taking part in this offering, including Janus Henderson Merchants, Adage Capital Companions LP, Woodline Companions, and Exome Asset Management.

This strategic funding marks a fundamental step in Everest’s ongoing efforts to give a boost to its self-discipline in next-expertise most cancers immunotherapy. It moreover displays the strong clinical and industry style complementarity and synergy between the two corporations. I-Mab’s Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated a formidable total response rate (ORR) of 83% along with immunotherapy in a Half 1b trial for first-line gastric most cancers. I-Mab’s differentiated 4-1BB receptor-focusing on platform and bispecific antibody pipeline are extremely complementary with Everest’s new mRNA most cancers vaccine and in vivo CAR-T platforms.

To boot to, I-Mab’s abnormal clinical translational capabilities, notably within the U.S., mixed with Everest’s clinical capabilities in Asia, would maybe well presumably relief scamper up the come and world growth of pipeline merchandise for every corporations.

“This strategic fairness funding furthers our understanding to be an energetic participant in next-expertise oncology programs at some level of world markets. Everest and its Board of Directors mumble this funding acknowledges I-Mab’s abnormal clinical translational capabilities within the U.S., that are complementary and synergistic with the Company’s strong Asia presence,” mentioned Rogers Yongqing Luo, Chief Govt Officer of Everest Medicines. “As a biotech pioneer in China, Everest has constructed internally developed pipeline sources including mRNA therapeutic most cancers vaccines and in vivo CAR-T therapies focusing on most cancers and autoimmune ailments. Our areas of focus meaningfully intersect with I-Mab’s differentiated 4-1BB platform and bispecific antibody pipeline, including oncology candidates Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and Ragistomig (PD-L1 x 4-1BB bispecific antibody), every promising programs that we are closely watching. Furthermore, every corporations would maybe well very effectively be in a self-discipline to leverage their mixed expertise to bustle clinical programs in every China and the U.S. Everest is proud to construct modern and precious therapies that can profit most cancers patients globally.”

The strategic fairness funding no longer simplest strengthens Everest Medicines’ self-discipline in next-expertise immuno-oncology, nonetheless moreover extends the realm style course of its proprietary AI-powered mRNA platform. As a key pillar of Everest’s “dual-engine” task of in-licensing and inner innovation, the corporate has made solid growth in building and internationalizing its AI+mRNA platform. A pair of pipeline programs are advancing in preclinical examine, with a sturdy tackle oncology and autoimmune ailments. Trying forward, Everest will scamper up world clinical style and regulatory efforts, whereas actively exploring collaborations with main international biopharmaceutical corporations to maximize the value of its platform and produce step forward therapies to patients worldwide.

Topic: Press originate summary

Source: Everest Medicines Restricted

Sectors: BioTech, Healthcare & Pharm

http://www.acnnewswire.com

From the Asia Company Recordsdata Network

Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Company Recordsdata Network.